Weight Loss Drug Success: Recent buzz on social media has centered around Eli Lilly and Company’s latest Phase 3 trial results for their next-generation weight loss drug, retatrutide. Many users are highlighting a significant stock jump following the announcement, with some noting a premarket increase of over 2%. The data, showing substantial weight loss and additional health benefits, has sparked lively discussions.
Market Momentum: Beyond the trial results, social media conversations are also focusing on the stock’s technical performance, with some pointing to a breakout from a descending trendline. There’s a sense of optimism as users discuss the potential for continued upward momentum. This has fueled debates on whether the company’s recent achievements will sustain long-term growth.
Note: This discussion summary was generated from an AI condensation of post data.
Eli Lilly and Company Insider Trading Activity
Eli Lilly and Company insiders have traded $LLY stock on the open market 302 times in the past 6 months. Of those trades, 9 have been purchases and 293 have been sales.
Here’s a breakdown of recent trading of $LLY stock by insiders over the last 6 months:
- ENDOWMENT INC LILLY has made 0 purchases and 290 sales selling 3,392,518 shares for an estimated $3,073,686,553.
- DONALD A ZAKROWSKI (SVP, Finance, & CAO) has made 0 purchases and 2 sales selling 2,000 shares for an estimated $1,745,430.
- DAVID A RICKS (President, Chair, and CEO) purchased 1,632 shares for an estimated $1,052,263
- J ERIK FYRWALD has made 2 purchases buying 1,565 shares for an estimated $1,005,242 and 0 sales.
- ILYA YUFFA (EVP&Pres, LLY USA&Global Capab) sold 1,250 shares for an estimated $783,762
- NAARDEN JACOB VAN (EVP & Pres., Lilly Oncology) purchased 1,000 shares for an estimated $647,360
- DANIEL SKOVRONSKY (EVP, CSO & Pres. LRL & LLY Imm) purchased 1,000 shares for an estimated $634,405
- RALPH ALVAREZ purchased 758 shares for an estimated $500,472
- LUCAS MONTARCE (EVP & CFO) purchased 715 shares for an estimated $494,626
- JAMERE JACKSON purchased 200 shares for an estimated $127,912
- GABRIELLE SULZBERGER purchased 117 shares for an estimated $75,018
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Eli Lilly and Company Revenue
Eli Lilly and Company had revenues of $17.6B in Q3 2025. This is an increase of 53.87% from the same period in the prior year.
You can track LLY financials on Quiver Quantitative's LLY stock page.
Eli Lilly and Company Congressional Stock Trading
Members of Congress have traded $LLY stock 12 times in the past 6 months. Of those trades, 7 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $LLY stock by members of Congress over the last 6 months:
- SENATOR JOHN BOOZMAN has traded it 3 times. They made 2 purchases worth up to $30,000 on 08/22, 08/11 and 1 sale worth up to $15,000 on 11/21.
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 11/18.
- REPRESENTATIVE JULIE JOHNSON has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 11/13, 08/14.
- SENATOR SHELLEY MOORE CAPITO purchased up to $15,000 on 10/24.
- REPRESENTATIVE VAL T. HOYLE sold up to $15,000 on 09/23.
- REPRESENTATIVE DAVID TAYLOR has traded it 2 times. They made 2 purchases worth up to $65,000 on 08/14 and 0 sales.
- REPRESENTATIVE LISA C. MCCLAIN has traded it 2 times. They made 1 purchase worth up to $15,000 on 07/10 and 1 sale worth up to $15,000 on 07/16.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
Eli Lilly and Company Hedge Fund Activity
We have seen 1,982 institutional investors add shares of Eli Lilly and Company stock to their portfolio, and 1,774 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 4,994,433 shares (+63.4%) to their portfolio in Q3 2025, for an estimated $3,810,752,379
- CAPITAL RESEARCH GLOBAL INVESTORS added 4,332,008 shares (+20.9%) to their portfolio in Q3 2025, for an estimated $3,305,322,104
- PRICE T ROWE ASSOCIATES INC /MD/ removed 3,366,669 shares (-20.0%) from their portfolio in Q3 2025, for an estimated $2,568,768,447
- CAPITAL WORLD INVESTORS removed 2,664,593 shares (-15.1%) from their portfolio in Q3 2025, for an estimated $2,033,084,459
- JPMORGAN CHASE & CO removed 2,242,818 shares (-17.9%) from their portfolio in Q3 2025, for an estimated $1,711,270,134
- GEODE CAPITAL MANAGEMENT, LLC added 1,689,260 shares (+9.3%) to their portfolio in Q3 2025, for an estimated $1,288,905,380
- TIGER GLOBAL MANAGEMENT LLC removed 1,511,160 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $1,153,015,080
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Eli Lilly and Company Analyst Ratings
Wall Street analysts have issued reports on $LLY in the last several months. We have seen 13 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- B of A Securities issued a "Buy" rating on 12/15/2025
- Wells Fargo issued a "Overweight" rating on 12/10/2025
- BMO Capital issued a "Outperform" rating on 12/04/2025
- Morgan Stanley issued a "Overweight" rating on 11/24/2025
- Bernstein issued a "Outperform" rating on 11/24/2025
- Truist Securities issued a "Buy" rating on 11/19/2025
- JP Morgan issued a "Overweight" rating on 11/18/2025
To track analyst ratings and price targets for Eli Lilly and Company, check out Quiver Quantitative's $LLY forecast page.
Eli Lilly and Company Price Targets
Multiple analysts have issued price targets for $LLY recently. We have seen 16 analysts offer price targets for $LLY in the last 6 months, with a median target of $1127.0.
Here are some recent targets:
- Tim Anderson from B of A Securities set a target price of $1268.0 on 12/15/2025
- Mohit Bansal from Wells Fargo set a target price of $1200.0 on 12/10/2025
- Evan Seigerman from BMO Capital set a target price of $1200.0 on 12/04/2025
- Courtney Breen from Bernstein set a target price of $1300.0 on 11/24/2025
- Terence Flynn from Morgan Stanley set a target price of $1290.0 on 11/24/2025
- Robyn Karnauskas from Truist Securities set a target price of $1182.0 on 11/19/2025
- Chris Schott from JP Morgan set a target price of $1150.0 on 11/18/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
